Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Trading Statement

5 Aug 2009 07:00

RNS Number : 8979W
PuriCore Plc
05 August 2009
 



PuriCore H1 2009 Trading Update 

Record Food Safety Shipments

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 5 August 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces a trading update covering the six months to 30 June 2009. Interim results for this period are expected to be announced on 25 August 2009. 

H1 2009 highlights:

Sales of $19.1 million, a decrease of 2% (an increase of 8% on a constant currency basis) (H1 2008: $19.5 million)

Food Safety sales of $12.6 million, an increase of 16%

Endoscopy sales of $6.1 million, a decrease of 27% (3% on a constant currency basis)

 

Cash balance as at 30 June 2009 of $15.8 million (increased from the cash balance as at 31 March 2009 of $15.6 million as a result of improved working capital and foreign currency)

Q2 operational cashflow positive

H1 operational cash outflow of $2.7 million (H1 2008: $4.8 million)

Debt reduced $2.7 million in H1 ($1.3 million in Q2)

 

Gross profit margins unchanged compared with H1 2008
Operating expense reductions of 14% (12% net of non-cash share compensation, depreciation and amortisation) compared with H1 2008 
Record 6-month shipments of 614 Sterilox Food Safety Systems

Post period-end developments (see separate release issued today):

Acquisition of Labcaire Systems Ltd., a leading UK supplier and manufacturer of endoscope disinfection equipment 

£2 million by way of a Placing through the issue of 10,810,811 Placing Shares at an Issue Price of 18.5 pence per share 

Outlook

PuriCore expects to complete the successful integration of Labcaire Systems into the business this year. The Company anticipates delivering full-year results for legacy PuriCore in line with market expectations for revenue growth and operating expenditure improvement. The Directors believe the Company is well positioned for further growth, and PuriCore will continue to make effective use of its balance sheet, including the strategic use of debt financing for leased systems.

Greg Bosch, Chief Executive of PuriCore, said:

 

"Wremain confident that we are well-positioned to execute on our legacy PuriCore business plan and look forward to integrating the Labcaire business in the UK as announced separately today."

Enquiries:

Ben Brewerton

Greg Bosch, CEO

Susan Quigley

Darren Weiss, VP of Finance

Financial Dynamics

PuriCore

+44 (0) 20 7831 3113

+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficileE.coli, HIV, Human and Animal Influenza (including H5N1 Avian Influenza), Legionella, MRSAM.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEASPSESFNEEE
Date   Source Headline
4th Jun 20144:46 pmRNSPublication of Circular
4th Jun 20147:00 amRNSSale of Endoscopy Business
14th May 20147:00 amRNSInterim Management Statement
24th Apr 20147:00 amRNSFinal Results
10th Apr 20147:00 amRNSNotice of Results
19th Feb 201411:22 amRNSBlocklisting Interim Review
18th Feb 20147:00 amRNSTrading Statement
13th Feb 20147:00 amRNSMiddle East Wound Care Marketing Agreement
7th Nov 20137:00 amRNSRe Agreement
6th Nov 20138:50 amRNSHolding(s) in Company
4th Nov 201310:03 amRNSHolding(s) in Company
1st Nov 20137:00 amRNSDirector/PDMR Shareholding
28th Oct 20137:00 amRNSInterim Management Statement
22nd Oct 20137:00 amRNSLaunches New Animal Health Wound Product NovaZo
15th Oct 20137:00 amRNSDirector Details
11th Oct 20137:00 amRNSReached agreement with Misonix
27th Sep 20137:00 amRNSValue Creation Plan Update
6th Sep 20131:58 pmRNSDirector Dealing
16th Aug 20133:24 pmRNSDirector Dealing
12th Aug 20131:59 pmRNSShare Option Grant
8th Aug 20137:00 amRNSHalf Yearly Report
2nd Aug 20137:00 amRNSBlocklisting Interim Review
17th Jul 20137:00 amRNSNotice of Results
28th Jun 20137:00 amRNSTotal Voting Rights
26th Jun 201311:19 amRNSResult of AGM
20th Jun 20137:00 amRNSPuriCore signs $13.5 million US deal
19th Jun 20131:16 pmRNSAGM Update
11th Jun 20133:08 pmRNSHolding(s) in Company
11th Jun 20133:06 pmRNSHolding(s) in Company
5th Jun 20131:13 pmRNSHolding(s) in Company - Replacement
5th Jun 20131:10 pmRNSHolding(s) in Company - Replacement
4th Jun 20133:04 pmRNSHolding(s) in Company
4th Jun 20133:01 pmRNSHolding(s) in Company
17th May 20137:46 amRNSInterim Management Statement
14th May 20137:00 amRNSBoard Changes
2nd May 20137:00 amRNSShare Option Grant
1st May 20137:00 amRNSTotal Voting Rights
30th Apr 20137:00 amRNSFinal Results
17th Apr 20131:57 pmRNSNotice of Results
8th Apr 20137:00 amRNSPuriCore Signs Major US Deal
3rd Apr 20137:00 amRNSPuriCore Signs Vashe Marketing Agreement
7th Mar 20137:00 amRNSTrading Update
6th Mar 20137:00 amRNSPuriCore Partners with Onset Dermatologics
5th Mar 20137:00 amRNSBoard and Organisational Changes
15th Feb 20135:20 pmRNSBlocklisting Interim Review
14th Feb 20137:00 amRNSFDA 510(k) Clearance
12th Feb 20136:01 pmRNSShare Option Grant and Blocklisting Update
7th Feb 20135:39 pmRNSApplication for Blocklisting
1st Feb 20134:40 pmRNSSecond Price Monitoring Extn
1st Feb 20134:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.